Here’s a simplified summary of the recent news from Biogen, Novartis, Resalis Therapeutics, and Moderna:
**Biogen**: The biotech company has made significant leadership changes. Daniel Quirk is the new Chief Medical Officer, coming from a senior role at Bristol Myers Squibb. Michael McDonnell, the Chief Financial Officer for four years, will retire in February and be succeeded by Robin Kramer. McDonnell was recognized for his contributions to important company projects and maintaining financial discipline.
**Novartis**: The company has reduced the estimated value of its recent acquisition of MorphoSys by $800 million. This is because of delays in the approval process for pelabresib, a drug for treating myelofibrosis, which Novartis expected to file for approval this year.
**Resalis Therapeutics**: Sanofi has invested in this Italian biotechnology company. Resalis is developing an RNA-based medicine aimed at treating metabolic diseases like obesity. They plan to start early-phase trials with this medicine soon, which could potentially improve the effectiveness of existing treatments.
**Moderna and Merck & Co.**: These companies are starting a new Phase 3 trial for their personalized cancer vaccine, tested with another drug, Keytruda, for early-stage lung cancer. They previously shared positive results from trials with melanoma patients. The ongoing trials are expected to be completed by 2029 and 2030.